Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in withdrawal due to adverse events compared with conventional dosing (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
It is very uncertain whether antihypertensive drug therapy changes withdrawal due to adverse events compared with control (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes withdrawals due to adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Four of the participants withdrew from the study by Kimos et al 2007 due to adverse effects, but neither the type of adverse effect nor the trial group was specified.
1 study · 44 participants
GRADE not reported
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
1 finding from 1 review